CHUNG SHAN MEDICAL UNIVERSITY

GLP-1 Drugs Show 16% Reduction in Epilepsy Risk Among Diabetes Patients in Large-Scale Study

- A preliminary study of 452,766 adults with type 2 diabetes found that GLP-1 drugs were associated with a 16% lower risk of developing epilepsy compared to DPP-4 inhibitors over five years. - Among the GLP-1 medications studied (dulaglutide, liraglutide, and semaglutide), semaglutide showed the strongest association with reduced epilepsy risk. - The observational study published in Neurology does not prove causation and requires randomized controlled trials for confirmation. - Researchers suggest the findings support theories that GLP-1 drugs may offer neurological benefits beyond blood sugar control for diabetes patients.